Related Experiment Video

Updated: Jun 22, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

[Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro]

Run-Zhang Lu1, Lin Qiu, Xiao-Dan Wang

  • 1Harbin Institute of Hematology & Oncology, Harbin 150010, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|July 1, 2009
PubMed
Abstract

Insights

Arsenic trioxide (As2O3) effectively inhibits imatinib-resistant bcr-abl mutant cell growth and induces apoptosis. This suggests As2O3 may be a promising therapeutic option for imatinib-resistant chronic myeloid leukemia (CML) patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib (IM) resistance is a significant challenge in chronic myeloid leukemia (CML) treatment.
  • BCR-ABL mutations are a primary mechanism of IM resistance in CML.
  • Novel therapeutic strategies are needed to overcome IM resistance.

Purpose of the Study:

  • To investigate the in vitro efficacy of arsenic trioxide (As2O3) against imatinib-resistant BCR-ABL mutant cell lines.
  • To evaluate the impact of As2O3 on cell growth, apoptosis, and key protein expression in resistant CML models.

Main Methods:

  • MTT assay was used to determine cell growth inhibition (IC50) of As2O3 and IM in sensitive and resistant cell lines.
  • Flow cytometry (Annexin V/PI staining) assessed apoptosis induction.
  • Western blot analyzed the expression of BCR-ABL fusion protein, phosphorylated CRKL, and apoptosis-related proteins.

Main Results:

  • As2O3 demonstrated significantly lower IC50 values in 15 IM-resistant cell lines compared to the IM-sensitive line.
  • As2O3 dose-dependently inhibited BCR-ABL fusion protein and phosphorylated CRKL expression.
  • As2O3 induced apoptosis through caspase-3, 8, and 9 pathways in frequently observed CML mutants.

Conclusions:

  • Arsenic trioxide exhibits potent anti-proliferative and pro-apoptotic effects on IM-resistant BCR-ABL mutant CML cell lines in vitro.
  • As2O3 shows potential as a therapeutic agent for patients with IM-resistant CML.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...